| STUDY
CATEGORY |
CURRENTLY ENROLLING |
ENROLLMENT
COMPLETE
|
| Antiretroviral
Trials (Naïve subjects) |
A
phase 3, randomized, open label,
study of Lopinavir/RTV tablets
versus soft gel capsules and
once daily versus twice daily
administration, when co-administered
with NRTI’s in antiretroviral
naïve HIV-1 infected subjects
|
|
| |
A
48-week, randomized, open-label,
2-arm study to compare
the efficacy of saquinavir/ritonavir
BID plus emtricitabine/tenofovir
QD versus lopinavir/ritonavir BID
plus emtricitabine/tenofovir QD
in treatment-naïve HIV-1 infected
patients (GEMINI) |
|
| |
|
A
randomized, controlled, open
label trial to compare the efficacy,
safety and tolerability of TMC114/RTV
versus lopinavir/RTV in treatment
naïve HIV-1 infected subjects.
This trial is referred to as
ARTEMIS. |
| |
|
A
Phase IIIB, Randomized, Open-Label,
Multicentre Study of
the Safety and Efficacy of GW433908
(700 mg BID) plus ritonavir (100
mg BID) Versus Lopinavir / ritonavir
(400 mg/100 mg BID) when Administered
in Combination with the Abacavir/Lamivudine
(600 mg/ 300 mg) Fixed-Dose Combination
Tablet QD in Antiretroviral-Naïve
HIV-1 Infected Adults Over 48 Weeks |
| |
|
A
Multicenter, Randomized, Double-Blind,
Comparative Trial Of A Novel
CCR5 Antagonist, UK 427,857,
In Combination With Zidovudine/Lamivudine
Versus Efavirenz in Combination
With Zidovudine/Lamivudine For
The Treatment of Antiretroviral-Naïve
HIV 1 Infected Subjects |
| Antiretroviral
Trials (Treatment-experienced
subjects) |
Vicriviroc
(SCH 417690) in Combination Therapy
with Optimized Antiretroviral
Regimen in Experienced Subjects
(VICTOR-E1) |
|
| |
|
A
phase IV, open label, randomized,
multicenter trial assessing a
Reyataz-based substitution approach
in the management of lipodystophy
syndrome. Research into Atazanavir
in Lipodystrophy (the REAL study) |
| |
|
A
phase II randomized, controlled,
partially blinded trial to investigate
dose response of TMC114/ritonavir(RTV)
in 3 class experienced HIV-1
infected subjects, followed by
an open label period on the recommended
dose of TMC114/ritonavir |
| |
|
An
open label trial of TMC114/RTV
in HIV-1 infected, treatment
experienced subjects |
| |
|
A
randomized, controlled, open
label trial to compare the efficacy,
safety and tolerability of TMC114/RTV
versus LPV/RTV in treatment experienced
HIV-1 infected subjects |
| |
|
A
Tri-National (Canada, UK, USA)
Randomised Controlled Trial To
Determine The Optimal Management
Of Patients With HIV Infection
For Whom First And Second-Line
Highly Active Antiretroviral
Therapy Has Failed. TNT-1: OPTIMA |
| |
|
A
Long-Term Open Label Roll-Over
Trial Assessing the Safety and
Tolerability of Combination Tipranavir
and Ritonavir Use in HIV-1 Infected
Subjects. BI1182.17 |
| |
|
A
Multicenter, Randomized, Double-Blind,
Placebo-Controlled Trial Of A
Novel CCR5 Antagonist, UK 427,857,
in Combination With Optimized
Background Therapy Versus Optimized
Background Therapy Alone For
The Treatment of Antiretroviral-Experienced
HIV 1 Infected Subjects |
| |
|
A
Multicenter, Randomized, Double-Blind,
Placebo-Controlled Trial Of A
Novel CCR5 Antagonist, UK 427,857,
In Combination With Optimized
Background Therapy Versus Optimized
Background Therapy Alone For
The Treatment of Antiretroviral-Experienced
Non CCR5-Tropic HIV 1 Infected
Subjects |
| |
|
A Phase III randomized,
double-blinded, placebo-controlled
trial to investigate the efficacy,
tolerability and safety of TMC125
as part of an ART including TMC114/RTV
and an investigator-selected OBR
in HIV-1 infected subjects with
limited to no treatment options.
TMC125-C216 |
| Structured
Treatment Interruptions |
|
A
large simple trial comparing
two strategies for management
of anti-retroviral therapy-smart
study (cpcra 065/ctn 190) |
| Women
(Including Pregnancy) |
A
phase IV, non-randomized, open
label trial evaluating the
safety of 625mg formulation of
Viracept® when administrated
to HIV-infected women during pregnancy |
|
| |
Predictors
of antiretroviral pharmacokinetics
in HIV-infected women with
virologic suppression on combination
antiretroviral therapy |
|
| Vaccine/Immunization |
A
pilot study assessing the efficacy
of pneumococcal vaccine in HIV
patients: delayed versus immediate
immunization |
|
| |
|
A
Randomized, Open Label, Phase
III, International Study of
Subcutaneous Recombinant IL-2
(Proleukin®) in Patients
With HIV-1 Infection and CD4+
Cell Counts >= 300/mm3:
Evaluation of Subcutaneous
Proleukin® in a Randomized
International Trial (ESPRIT) |
| Hepatitis |
If
hepatitis C (HCV) is an opportunistic
infection, why has HAART not
led to dramatic improvements
in liver disease amoung HIV-HCV
co-infected patients? |
|
| |
|
A
Randomized, placebo controlled
trial of Citalopram for the prevention
of depression and its consequences
in HIV-Hepatitis C co-infected
individuals initiating Peglyated
Interferon/Ribavirin therapy |
| Anal
Cancer Screening |
|
Early
anal cancer screening study using
anal pap smears, high resolution
anoscopy and directed biopsy.
Toronto Research in Anal Cytology
Evaluation (TRACE study). |
Side Effects/Toxicity |
A
Case-control Toxicogenomics Study
to identify Unique Genetic Polymorphisms
in Patients who have experienced
symptomatic Hepatotoxicity or
Severe Cutaneous Toxicity within
the first 8 weeks of Nevirapine
Therapy |
|
